^
Association details:
| Biomarker: | CCND1 amplification |
|---|---|
| Cancer: | Melanoma |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.
Excerpt:
Among 70 evaluable pts, 2 (2.9%; 600 mg/d) had confirmed PRs: 1 pt with PIK3CA-mut, CCND1-amp, ER+ breast cancer; 1 pt with BRAF/NRAS-WT, CCND1-amp melanoma. SD for ≥4 and ≥6 cycles was seen in 26% and 14% of pts, respectively.
DOI:
10.1200/jco.2014.32.15_suppl.2528
Trial ID:
